{"date":"2025-05-01","count":4,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6659-2025-05-01-1647-19uqy17","company_id":"6659","company":"天明製藥","market":"興櫃","industry":"生技醫療","date":"2025-05-01","time":"16:47:07","subject":"公告本公司因配合簽證會計師事務所內部調整更換會計師。","clause":"第7款","fact_date":"2025-05-01","cite_as":"公開資訊觀測站重大訊息：天明製藥（6659），2025-05-01 16:47，「公告本公司因配合簽證會計師事務所內部調整更換會計師。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1799-2025-05-01-1452-5b6u45","company_id":"1799","company":"易威","market":"上櫃","industry":"生技醫療","date":"2025-05-01","time":"14:52:33","subject":"代子公司美國Tulex Pharmaceuticals公告,共同開發新藥(505(b)(2)）液態口服治療尿崩症藥品,已向美國FDA提出新劑型新藥查驗登記申請(NDA)","clause":"第10款","fact_date":"2025-05-01","cite_as":"公開資訊觀測站重大訊息：易威（1799），2025-05-01 14:52，「代子公司美國Tulex Pharmaceuticals公告,共同開發新藥(505(b)(2)）液態口服治療尿崩症藥品,已」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4174-2025-05-01-0857-pa4ltt","company_id":"4174","company":"浩鼎","market":"上櫃","industry":"生技醫療","date":"2025-05-01","time":"08:57:07","subject":"本公司OBI-902 TROP2 ADC新藥獲得美國食品藥物管理局(FDA)核准進行一/二期人體臨床試驗","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：浩鼎（4174），2025-05-01 08:57，「本公司OBI-902 TROP2 ADC新藥獲得美國食品藥物管理局(FDA)核准進行一/二期人體臨床試驗」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7754-2025-05-01-0825-cgjw0h","company_id":"7754","company":"安基生技","market":"興櫃","industry":"生技醫療","date":"2025-05-01","time":"08:25:59","subject":"補充說明114年04月24日之重大訊息","clause":"第44款","fact_date":"2025-04-24","cite_as":"公開資訊觀測站重大訊息：安基生技（7754），2025-05-01 08:25，「補充說明114年04月24日之重大訊息」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}